Ampersand Medical
This article was originally published in The Gray Sheet
Executive Summary
Offers to acquire AccuMed International's AcCell 2000, 2001 and 3000 cytopathology systems used in the diagnosis of Pap smears and other cytology specimens. Ampersand also seeks to acquire "all intellectual properties" related to the technologies and AccuMed's contracted customer base, the privately held Chicago firm says. The offer "includes cash plus a royalty and a license back to AccuMed for certain technology owned by Ampersand that may be used on AccuMed's Savant system"